PITTSBURGH, PA (July 27, 2005) – Neuro Kinetics, Inc. (NKI), manufacturers of medical diagnostic equipment used worldwide, said today that it has closed the first phase of its Series B equity raise.

The company said it has secured $400,000 of its planned $1 million in new financing.

"We are gratified that our new investors share our vision for our company," said Howison Schroeder, NKI CEO. "Our company has tremendous opportunity in the near future as we enhance our existing product line, introduce new products and strengthen our sales and marketing initiatives around the world."

NKI manufactures neuro-otologic diagnostic devices used clinically for balance and dizziness testing in hospitals and other healthcare facilities, and for advanced research by universities, government agencies and others. The company's products currently are in use by neurologists, otolaryngologists, audiologists, ophthalmologists, vestibular researchers and others across North America, and in Australia, Asia and Europe.

NKI soon will introduce its next generation I-Portal^® eye-tracking device designed for widespread use by doctors in their offices, as well as in hospitals and clinics.

The company pioneered the development of the motorized, modern Barany (rotating) Chair Systems.

"Accurately and dynamically measuring eye movements related to neuro-otology and neuro-ophthalmology as a cause of dizziness is key to finding new, cost-effective preventive solutions to a wide array of diseases and medical disorders," said Schroeder. "As societies around the world grapple with the needs of aging populations while also more efficiently managing healthcare costs, we believe we are well positioned for continued success."

For more information, please visit http://www.neuro-kinetics.com/.

MEDIA CONTACT

John Buckman
Buckman Communications, for Neuro Kinetics, Inc.
+1 412.381.2900 or jbuckman@buckman.biz